DIFLUZOL

Cryptococcosis, including cryptococcal meningitis and infections of other localizations (such as lung, skin). Treatment of AIDS patients and carriers, and patients after organs transplantation and other patients who treated with immunodepressants. Fluconazole can be administered as supportive treatment for a prophylactic of cryptococcal recurrences and AIDS patients. Generalized candidiasis, including candidemia, disseminated candidiasis and other forms of invasive candidasis infections (lesions of abdominal cavity, endocardial lesions, lesions of the eye, respiratory and urinary tract lesions). Treatment of patients with malignant neoplasms, which are located in intensive care unit and treated with cytostatic and immunosuppressive therapy or are impacted by other factors that make them more liable to candidiasis development. Candidiasis of mucous membranes: oropharynx lesions, esophagus, non-invasive bronchopulmonary infection, candiduria, mucocutaneous and chronic atrophic candidiasis (candidiasis caused by dental prosthesis). Treatment of carriers and AIDS patients. Prevention of recurrence of oropharyngeal candidiasis in AIDS patients. Genital candidiasis, including vaginal candidiasis, acute or recurrent, and candidal balanitis. Prophylactic administration to decrease the frequency of recurrence of vaginal candidiasis (3 or more recurrences per year). Prevention of fungal infections with malignant tumors in patients that are inclined to such infections that are a result of chemotherapy or radiation therapy. Dermatomycosis – foot mycosis, glabrous skin mycosis, ringworm of the groin, pityriasis versicolor, ringworm of the nails, cutaneous candida infections. Deep endemic mycoses - in patients with unaffected immune systems, coccidomycosis, paracoccidiomikoz, sporotrichosis and histoplasmosis.